Skip to content
Alunbrig(brigatinib)
Alunbrig (brigatinib) is a small molecule pharmaceutical. Brigatinib was first approved as Alunbrig on 2017-04-28. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Alunbrig
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brigatinib
Tradename
Company
Number
Date
Products
ALUNBRIGTakedaN-208772 RX2017-04-28
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
alunbrigNew Drug Application2020-05-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
Agency Specific
FDA
EMA
Expiration
Code
BRIGATINIB, ALUNBRIG, TAKEDA PHARMS USA
2027-05-22ODE-300
2024-04-28ODE-142
2023-05-22I-847
Patent Expiration
Patent
Expires
Flag
FDA Information
Brigatinib, Alunbrig, Takeda Pharms Usa
103850782035-11-10DS, DPU-2837
96112832034-04-10U-2837
90124622031-04-28DP
92730772029-05-21U-2837
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01ED: Anaplastic lymphoma kinase (alk) inhibitors
— L01ED04: Brigatinib
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022894132—523
Lung neoplasmsD008175C34.90331—18
NeoplasmsD009369C80241—16
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large-cell lymphoma anaplasticD017728C84.623———3
Breast neoplasmsD001943EFO_0003869C50—1———1
Gastrointestinal neoplasmsD005770C26.9—1———1
Brain neoplasmsD001932EFO_0003833C71—1———1
Neurofibromatosis 2D016518Q85.02—1———1
Acoustic neuromaD009464HP_0009588—1———1
MeningiomaD008579EFO_0003098D32.9—1———1
EpendymomaD004806—1———1
Gene amplificationD005784—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gene rearrangementD0153212————2
CarcinomaD002277C80.01————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBRIGATINIB
INNbrigatinib
Description
Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1
Identifiers
PDB—
CAS-ID1197953-54-0
RxCUI1921217
ChEMBL IDCHEMBL3545311
ChEBI ID—
PubChem CID68165256
DrugBankDB12267
UNII IDHYW8DB273J (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Alunbrig - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,821 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8,597 adverse events reported
View more details